Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Conversion of all Class A Shares in Medivir to Class B Shares - Prospectus Published

Posted on: 31 Mar 18

STOCKHOLM, March 28, 2018 /PRNewswire/ -- Medivir AB ("Medivir" or the "Company") (Nasdaq Stockholm: MVIR) today announces that the prospectus, which has been prepared as a result of the conversion of all class A shares in Medivir to class B shares, is now available on Medivir's website, The prospectus is also available at Medivir's office, Lunastigen 7, SE-141 44 Huddinge, Sweden, and can be ordered from Medivir by phone +46(0)8 5468 31 00.

The conversion entails that all shares in the Company will be class B shares. As each class A share carries ten votes and each class B share carries one vote, the conversion of the class A shares, 474,769 in total, means that the aggregate number of votes in Medivir decreases from 28,560,739 to 24,287,818. The total number of shares in Medivir is not affected. The new class B shares will start trading at Nasdaq Stockholm around 5 April 2018.

For further information, please contact:

Erik Björk
Medivir AB
Phone: +46(0)72-228-2831

About Medivir

Medivir is a research-based pharmaceutical company with a focus on oncology. We have a leading competence within protease inhibitor design and nucleotide/nucleoside science and we are dedicated to develop innovative pharmaceuticals that meet great unmet medical needs. Medivir is listed on the Nasdaq Stockholm Mid Cap List (ticker: MVIR).

This information was brought to you by Cision,c2483409

Editor's Details

Mike Wood

Last updated on: 31/03/2018

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.